Insider Buying: Kura Oncology Inc (KURA) Major Shareholder Buys 40,538 Shares of Stock

Kura Oncology Inc (NASDAQ:KURA) major shareholder Ecor1 Capital Fund Qualified, bought 40,538 shares of Kura Oncology stock in a transaction that occurred on Thursday, December 13th. The shares were acquired at an average price of $13.90 per share, with a total value of $563,478.20. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ecor1 Capital Fund Qualified, also recently made the following trade(s):

  • On Thursday, December 6th, Ecor1 Capital Fund Qualified, bought 119,906 shares of Kura Oncology stock. The shares were acquired at an average price of $13.50 per share, with a total value of $1,618,731.00.

Shares of KURA stock opened at $14.03 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.76 and a quick ratio of 14.76. Kura Oncology Inc has a one year low of $10.20 and a one year high of $24.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. Sell-side analysts anticipate that Kura Oncology Inc will post -1.72 EPS for the current year.

A number of analysts have commented on KURA shares. BidaskClub upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, September 29th. Zacks Investment Research cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. ValuEngine cut shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 19th. Piper Jaffray Companies set a $25.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a research note on Monday, December 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Kura Oncology in a research note on Monday, December 3rd. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Kura Oncology currently has a consensus rating of “Buy” and an average target price of $26.86.

Hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. acquired a new stake in Kura Oncology in the second quarter valued at $2,412,000. Swiss National Bank acquired a new stake in shares of Kura Oncology during the 2nd quarter worth about $768,000. Prosight Management LP acquired a new stake in shares of Kura Oncology during the 2nd quarter worth about $5,240,000. BlackRock Inc. lifted its stake in shares of Kura Oncology by 25.5% during the 2nd quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock worth $36,440,000 after buying an additional 406,963 shares during the last quarter. Finally, Sio Capital Management LLC lifted its stake in shares of Kura Oncology by 27.4% during the 2nd quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock worth $15,244,000 after buying an additional 180,193 shares during the last quarter. Hedge funds and other institutional investors own 79.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Kura Oncology Inc (KURA) Major Shareholder Buys 40,538 Shares of Stock” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.wkrb13.com/2018/12/16/insider-buying-kura-oncology-inc-kura-major-shareholder-buys-40538-shares-of-stock.html.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: Systematic Risk

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply